Video - European Medical Journal

Continue

Videos

EMJ
Oncology
25 May 2016

Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…
EMJ
Oncology
25 May 2016

Immunotherapy for hepatocellular carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS…
EMJ
Oncology
25 May 2016

Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD…
EMJ
Oncology
25 May 2016

Endocrine therapy in pregnant women with breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…
EMJ
Oncology
25 May 2016

Olaparib and bevacizumab: On the horizon for treating ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS…
EMJ
Oncology
25 May 2016

Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…
Oncology
25 May 2016

From biologics to biosimilars

A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the…
Rheumatology
19 Apr 2016

Treating Active HIDS with Canakinumab

The efficacy and safety of canakinumab in active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS) and the implications of the results for the future treatment of patients with the condition.